Clinical endoscopy · 2017
There Is No Advantage to Transpapillary Pancreatic Duct Stenting for the Transmural Endoscopic Drainage of Pancreatic Fluid Collections: A Meta-Analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amin Sunil, Yang Dennis J, Lucas Aimee L, Gonzalez Susana, DiMaio Christopher J
Аннотация
BACKGROUND/AIMS: Options for the endoscopic management of symptomatic pancreatic fluid collections (PFCs) include transmural drainage (TM) alone, transpapillary drainage (TP) alone, or a combination of both drainage method (CD). There have been conflicting reports about the best method. This study performed a meta-analysis to determine whether CD presents an added clinical benefit over TM.
METHODS: The included studies compared TM with CD and reported clinical success for both methods. A random-effects model was used to determine the pooled odds ratios (ORs) and the 95% confidence intervals (CIs) for the following outcomes: technical success, clinical success, complications, and recurrence.
RESULTS: Nine studies involving a combined total of 604 drainage procedures-373 TMs (62%) and 231 CDs (38%)-were included. CD showed no additional benefit over TM in terms of technical success (OR, 1.12; 95% CI, 0.37-3.37; p=0.85), clinical success (OR, 1.11; 95% CI, 0.65-1.89; p=0.70), recurrence (OR, 1.49; 95% CI, 0.53-4.21; p=0.45), or complications (OR, 1.15; 95% CI, 0.61-2.18; p=0.67).
CONCLUSIONS: Pancreatic duct (PD) stenting provides no additional clinical benefit for the TM of PFCs (particularly pseudocysts). Patients undergoing the TM of symptomatic pseudocysts may not require endoscopic retrograde pancreatography (ERP).
METHODS: The included studies compared TM with CD and reported clinical success for both methods. A random-effects model was used to determine the pooled odds ratios (ORs) and the 95% confidence intervals (CIs) for the following outcomes: technical success, clinical success, complications, and recurrence.
RESULTS: Nine studies involving a combined total of 604 drainage procedures-373 TMs (62%) and 231 CDs (38%)-were included. CD showed no additional benefit over TM in terms of technical success (OR, 1.12; 95% CI, 0.37-3.37; p=0.85), clinical success (OR, 1.11; 95% CI, 0.65-1.89; p=0.70), recurrence (OR, 1.49; 95% CI, 0.53-4.21; p=0.45), or complications (OR, 1.15; 95% CI, 0.61-2.18; p=0.67).
CONCLUSIONS: Pancreatic duct (PD) stenting provides no additional clinical benefit for the TM of PFCs (particularly pseudocysts). Patients undergoing the TM of symptomatic pseudocysts may not require endoscopic retrograde pancreatography (ERP).